AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s latest clinical study, titled A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01), aims to evaluate the efficacy and safety of AZD0901. This study focuses on patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin18.2, a significant target in cancer treatment.
The intervention being tested is AZD0901, an investigational drug administered via intravenous infusion. It is designed to target Claudin18.2, potentially offering a new treatment option for patients who have progressed beyond first-line therapies.
The study is interventional, with a randomized, parallel assignment model. It is sponsor-blinded, meaning AstraZeneca will not access treatment records during the study. The primary purpose is treatment, with outcomes assessed by masked evaluators to ensure unbiased results.
The study began on March 4, 2024, with the last update submitted on August 12, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
For investors, the success of AZD0901 could significantly impact AstraZeneca’s stock performance, as it would introduce a novel treatment in a competitive cancer therapy market. The study’s outcome could also influence investor sentiment and position AstraZeneca ahead of competitors targeting similar cancer types.
The study is ongoing, with further details available on the ClinicalTrials portal.